ArticleJournal of thoracic disease2023

Efficacy and safety of anti-programmed cell death protein 1 antibody combination therapy in patients with advanced experienced epidermal growth factor receptor-tyrosine kinase inhibitor-resistant lung adenocarcinoma: a retrospective cohort study.

Chang Wan et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.